Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
API
0
FDF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. (3s,11ar)-n-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
2. Apretude
3. Cabotegravir Extended-release Injectable Suspension
4. Cabotegravir Sodium
5. Gsk-1265744
6. Gsk-1265744a
7. Gsk-1265744b
8. Gsk1265744
9. Gsk1265744a
10. Gsk1265744b
11. Gsk744
12. N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
13. S-265744
14. S-265744b
15. Sodium (3s,11ar)-8-(((2,4-difluorophenyl)methyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazin-6-olate
16. Vocabria
1. 1051375-10-0
2. Gsk1265744
3. Gsk744
4. Gsk-1265744
5. Gsk1265744a
6. S-265744
7. Gsk744 Lap
8. Gsk-1265744a
9. Gsk744 La
10. Gsk 744
11. S/gsk1265744
12. Gsk 1265744
13. Cabotegravir (gsk744, Gsk1265744)
14. Gsk744 (s/gsk1265744)
15. Hmh0132z1q
16. (3s,11ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
17. Cab
18. (3s,11ar)-n-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
19. Unii-hmh0132z1q
20. Cabotegravir [usan:inn]
21. Cabotegravirum
22. 744 La
23. Cabotegravir [inn]
24. Cabotegravir [jan]
25. Cabotegravir [usan]
26. Schembl82803
27. Cabotegravir [who-dd]
28. Cabotegravir (jan/usan/inn)
29. Cabotegravir; Gsk1265744
30. Chembl2403238
31. Gtpl11386
32. Dtxsid50146982
33. Chebi:172944
34. Cabotegravir [orange Book]
35. Amy27899
36. Bcp08631
37. Ex-a2330
38. Bdbm50492496
39. Mfcd25976748
40. S7766
41. Zinc96927633
42. Cabenuva Component Cabotegravir
43. S/gsk-1265744
44. Cabenuva (cabotegravir + Rilpivirine)
45. Ccg-268708
46. Cs-5078
47. Db11751
48. Cabotegravir Component Of Cabenuva
49. Ncgc00386434-02
50. Ac-30895
51. As-61279
52. Hy-15592
53. S/gsk1265744; Gsk744
54. D10548
55. P14046
56. A902375
57. Q15411012
58. (3r,6s)-n-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0?,?]trideca-9,12-diene-12-carboxamide
59. (3r,6s)-n-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
60. (3s,11ar)-n-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
61. (3s,11ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
62. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
63. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,11,11a-tetrahydrooxazolo[[?]]pyrido[[?]]pyrazine-8-carboxamide
64. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
65. 1264720-72-0
66. N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
67. Oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide, N-((2,4-difluorophenyl)methyl)-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3s,11ar)-
Molecular Weight | 405.4 g/mol |
---|---|
Molecular Formula | C19H17F2N3O5 |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 3 |
Exact Mass | 405.11362698 g/mol |
Monoisotopic Mass | 405.11362698 g/mol |
Topological Polar Surface Area | 99.2 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 814 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Oral cabotegravir is indicated in combination with rilpivirine for the short term treatment of HIV-1 in virologically suppressed adults with no history of treatment failure to assess tolerability of cabotegravir or who have missed an injected dose of cabotegravir. Intramuscular extended-release cabotegravir is indicated in combination with rilpivirine as a complete regimen for virologically suppressed adults with no history of treatment failure. The intramuscular form is meant to replace their current antiretroviral treatment.
Treatment of human immunodeficiency virus (HIV-1) infection
Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:
- oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting cabotegravir injection plus long acting rilpivirine injection.
- oral therapy for adults who will miss planned dosing with cabotegravir injection plus rilpivirine injection.
Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.
Treatment of human immunodeficiency virus (HIV-1) infection
Prevention of human immunodeficiency virus (HIV-1) infection
Cabotegravir is an inhibitor of HIV integrase, which reduces viral replication. It has a long duration of action as the oral tablet is given daily and the intramuscular suspension is given monthly. Patients should be counselled regarding the risk of hypersensitivity, hepatotoxicity, and depression.
HIV Integrase Inhibitors
Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA. (See all compounds classified as HIV Integrase Inhibitors.)
J05AX
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AJ - Integrase inhibitors
J05AJ04 - Cabotegravir
Absorption
Oral cabotegravir has a Tmax of 3 hours, reaches a Cmax of 8.0 g/mL, and has an AUC of 145 g\*h/mL. Intramuscular extended-release cabotegravir has a Tmax of 7 days, reaches a Cmax of 8.0 g/mL, and has an AUC of 1591 g\*h/mL.
Route of Elimination
An oral radiolabelled dose of cabotegravir is 58.5% recovered in the feces and 26.8% recovered in the urine.
Volume of Distribution
Data regarding the volume of distribution of cabotegravir is not readily available.
Clearance
Data regarding the clearance of cabotegravir is not readily available. Clearance in dogs was 0.34 mL/min/kg and in cynomolgus monkeys was 0.32 mL/min/kg.
Cabotegravir is O-glucuronidated to the M1 and M2 metabolites, with 67% of glucuronidation performed by UGT1A1, and 33% by UGT1A9.
The mean half life of oral cabotegravir is 41 hours. The mean half life of intramuscular extended-release cabotegravir is 5.6-11.5 weeks.
Cabotegravir binds to the active site of HIV integrase, preventing strand transfer of the viral genome into the host genome, and preventing replication of the virus.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
12
PharmaCompass offers a list of Cabotegravir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cabotegravir manufacturer or Cabotegravir supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cabotegravir manufacturer or Cabotegravir supplier.
PharmaCompass also assists you with knowing the Cabotegravir API Price utilized in the formulation of products. Cabotegravir API Price is not always fixed or binding as the Cabotegravir Price is obtained through a variety of data sources. The Cabotegravir Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cabotegravir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabotegravir, including repackagers and relabelers. The FDA regulates Cabotegravir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabotegravir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cabotegravir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cabotegravir supplier is an individual or a company that provides Cabotegravir active pharmaceutical ingredient (API) or Cabotegravir finished formulations upon request. The Cabotegravir suppliers may include Cabotegravir API manufacturers, exporters, distributors and traders.
click here to find a list of Cabotegravir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cabotegravir DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabotegravir active pharmaceutical ingredient (API) in detail. Different forms of Cabotegravir DMFs exist exist since differing nations have different regulations, such as Cabotegravir USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cabotegravir DMF submitted to regulatory agencies in the US is known as a USDMF. Cabotegravir USDMF includes data on Cabotegravir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabotegravir USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cabotegravir suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cabotegravir Drug Master File in Korea (Cabotegravir KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabotegravir. The MFDS reviews the Cabotegravir KDMF as part of the drug registration process and uses the information provided in the Cabotegravir KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cabotegravir KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabotegravir API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cabotegravir suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabotegravir as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cabotegravir API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cabotegravir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cabotegravir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabotegravir NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cabotegravir suppliers with NDC on PharmaCompass.
Cabotegravir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cabotegravir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabotegravir GMP manufacturer or Cabotegravir GMP API supplier for your needs.
A Cabotegravir CoA (Certificate of Analysis) is a formal document that attests to Cabotegravir's compliance with Cabotegravir specifications and serves as a tool for batch-level quality control.
Cabotegravir CoA mostly includes findings from lab analyses of a specific batch. For each Cabotegravir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cabotegravir may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabotegravir EP), Cabotegravir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabotegravir USP).